News Release

 

Back
 

AmerisourceBergen Reports Record Revenue and Earnings for First Quarter Fiscal Year 2002; First Quarter EPS Up 37 Percent To $0.67 Before Special Item

01/24/02

Operating Revenue Increased 20% Over Pro Forma Prior Year AmerisourceBergen Corporation today reported record results for its fiscal first quarter ended December 31, 2001.

VALLEY FORGE, Pa.--(BUSINESS WIRE)--Jan. 24, 2002-- AmeriSource Health Corporation and Bergen Brunswig Corporation merged on August 29, 2001 to form AmerisourceBergen Corporation (NYSE:ABC) . Under purchase accounting rules, AmerisourceBergen's fiscal 2002 first quarter results are compared with the fiscal 2001 first quarter of AmeriSource only.

Pro forma data included in this discussion reflects comparisons to the combined companies operating results in the previous year's first quarter, adjusted to eliminate amortization of goodwill. Both former companies had the same fiscal year ending September 30.

AmerisourceBergen's operating revenue, which excludes bulk deliveries to customer warehouses, was a record $9.7 billion in the first quarter compared to $3.3 billion for the same period last year. First quarter operating revenue increased 20 percent over fiscal 2001 first quarter pro forma operating revenue of $8.1 billion.

Diluted earnings per share before the special item for the quarter were $0.67, a 37 percent increase over the previous year's first quarter. Income before the special item for the first quarter increased to $72.4 million from $26.2 million in the same period last year. The special item, consisting of merger integration costs, was a $4.5 million charge, net of tax, in the quarter.

Net income and diluted earnings per share for the quarter were $67.9 million and $0.63, respectively. AmerisourceBergen had approximately 111.2 million weighted average diluted common shares outstanding for the first quarter of fiscal 2002.

The following discussion of the first quarter results, including segment data, does not include the impact of the special item in first quarter of fiscal 2002.

R. David Yost, AmerisourceBergen President and Chief Executive Officer, said, "This was an exceptional performance by AmerisourceBergen in its first full quarter as a combined company. The Company delivered strong revenue growth, record earnings per share, and a very strong return on committed capital (ROCC) of 25.4 percent.

"This solid revenue and earnings performance is a clear indication of the strength of this new company. Our diverse customer base, our focus on the pharmaceutical supply chain, and our developing scale, all contributed to our success in the quarter.

"Our cost savings from merger synergies are gaining traction. In 120 days, we have established our management organization, completed our planning activities for capturing merger synergies, and begun to operate as one company, while remaining focused on customer service."

Segment Discussion

AmerisourceBergen operates in two segments: Pharmaceutical Distribution (which includes AmerisourceBergen Drug Company and AmerisourceBergen Specialty Group) and PharMerica, its institutional pharmacy and worker's compensation fulfillment businesses.

Intersegment sales of $191.2 million in the first quarter of fiscal 2002 from AmerisourceBergen Drug Company to PharMerica, which are included in the pharmaceutical distribution segment operating revenue, are eliminated for consolidated reporting purposes.

Pharmaceutical Distribution Segment

Operating revenue in the first quarter of fiscal 2002 increased to $9.5 billion compared with $3.3 billion, in the previous year's first quarter. Operating revenue increased 20 percent over fiscal 2001 first quarter pro forma revenues of $7.9 billion.

Pharmaceutical distribution customer mix in the first quarter of fiscal 2002 was 52 percent institutional and 48 percent retail.

Operating income was $139.5 million in the first quarter of fiscal year 2002, up from $53.9 million for the same quarter last year, and improved 20 percent compared to pro forma operating income of $116.1 million in the same period last year.

For the fiscal 2002 first quarter, operating income, as a percentage of operating revenue, was 1.46 percent, unchanged compared to the prior year's first quarter results on a pro forma basis. Consistent with prior experience, lower gross margins were offset by lower total operating expenses as a percentage of operating revenue.

"This quarter's strong revenue growth in pharmaceutical distribution was driven primarily by new accounts added in previous quarters, new business opportunities with existing customers, and above market growth rates in our larger retail and institutional customers," said Kurt Hilzinger, AmerisourceBergen Executive Vice President and Chief Operating Officer. "These growth dynamics in combination with solid expense control drove excellent earnings growth in the quarter."

"With annualized revenue now over $2 billion, AmerisourceBergen Specialty Group continues its rapid development as it builds on its strong positions in oncology, blood plasma and vaccine distribution," he said.

Commenting on integration activities, Hilzinger said, "We continue to make significant progress in all facets of our integration activities, remaining on or ahead of our established timetables. During the quarter we closed two distribution centers, consolidated our pharmaceutical repackaging operations and began capturing procurement and administrative savings.

"Our information technology integration work remains on track allowing for five more distribution centers to be consolidated before the end of the fiscal year, and we continue our planning activities for the six new distribution centers we expect to build."

PharMerica

PharMerica's operating revenue for the first quarter of fiscal 2002 was $355.4 million, representing a 6 percent increase over pro forma operating revenue of $335.2 million in the same period last year.

Operating income for the first quarter was $19.3 million, a 13 percent increase over the previous year's pro forma first quarter operating income of $17.1 million.

Operating income as a percentage of operating revenue increased 33 basis points in the quarter to 5.43 percent from 5.10 percent on a pro forma basis. As anticipated, lower gross margins were more than offset by lower total operating expenses as a percentage of operating revenue.

"PharMerica's disciplined growth and expense control continued to drive its improved performance in the quarter," said Hilzinger. "Asset management has improved as illustrated by reductions in gross days-sales-outstanding (DSO), which were 63 in the quarter, down from 82 in the same quarter last year. Net DSOs dropped from 55 in the prior year's first quarter to 44 in the current first quarter."

Looking Ahead

"For the balance of fiscal 2002, we expect continued strong performance for AmerisourceBergen with revenue growth in the range of 15 percent to 17 percent and ROCC in excess of 20 percent," said Yost. "We are increasing our diluted earnings per share estimate for fiscal year 2002, excluding the impact of merger-related special items, from $2.90 to $3.00. The increase in earnings expectations for the year reflects the strong performance of our businesses in the first quarter, continued low interest rates, and our ongoing focus on cost improvement.

We remain confident in our ability to achieve annual cost saving synergies of $150 million by the end of fiscal year 2004."

Conference Call

The Company will host a conference call to discuss the results at 11:00 am Eastern Standard Time on January 24, 2002. Participating in the conference call will be: R. David Yost, President & Chief Executive Officer; Kurt J. Hilzinger, Executive Vice President & Chief Operating Officer; and Neil F. Dimick, Executive Vice President & Chief Financial Officer.

To access the live conference call via telephone:

Dial in: 800/553-0318 from inside the U.S. no access code required

             or 612/288-0340 from outside the U.S. no access code 
             required .

To access the live webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net.

A replay of the telephone call and webcast will be available from 2:30 pm January 24, 2002 until 11:59 pm January 31, 2002.

To access the replay via telephone:

Dial in: 800/475-6701 from within the U.S., access code: 620238

320/365-3844 from outside the U.S., access code: 620238

To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.net.

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems/acute care market, alternative care facilities, independent community pharmacies, and regional chains.

The Company is also a leader in the institutional pharmacy marketplace. With more than $36 billion in annualized operating revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

Forward-Looking Statements

This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger between Amerisource Health Corporation and Bergen Brunswig Corporation.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally.

More detailed information about these factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2001 and AmeriSource's and Bergen's joint proxy statement-prospectus dated August 1, 2001.

AmerisourceBergen, AmeriSource and Bergen Brunswig are under no obligation to (and expressly disclaim any such obligation to) update or alter their forward-looking statements whether as a result of new information, future events or otherwise.

                     AMERISOURCEBERGEN CORPORATION
                           FINANCIAL SUMMARY
                 (In thousands, except per share data)
                              (unaudited)


                     Three                  Three
                 Months Ended    % of    Months Ended   % of
                    Dec. 31,   Operating   Dec. 31,   Operating    %
                      2001      Revenue      2000      Revenue  Change
                   ----------   ------    ----------   ------    ----

Revenue:
  Operating
   revenue         $9,686,276   100.00%   $3,306,751   100.00%   193%
  Bulk
   deliveries
   to customer
   warehouses       1,382,504                    444              --
                   ----------             ----------
Total revenue      11,068,780              3,307,195             235%

Cost of goods
 sold              10,597,347              3,169,762             234%
                   ----------             ----------

Gross profit          471,433     4.87%      137,433     4.16%   243%

Operating
 expenses:
  Distribution,
   selling and
   administrative     297,592     3.07%       79,645     2.41%   274%
  Depreciation
   and
   amortization        15,047     0.16%        3,894     0.12%   286%
  Merger costs          7,497     0.08%           --     0.00%    --
                   ----------             ----------

Operating income      151,297     1.56%       53,894     1.63%   181%

Equity in losses
 of affiliates
 and other              1,731     0.02%          774     0.02%   124%

Interest expense       30,975     0.32%       10,876     0.33%   185%
                   ----------             ----------

Income before
 taxes and
 distributions
 on preferred
 securities of
 subsidiary trust     118,591     1.22%       42,244     1.28%   181%

Income taxes           47,078     0.49%       16,053     0.49%   193%
                   ----------             ----------

Income before
 distributions on
 preferred
 securities of
 subsidiary trust      71,513     0.74%       26,191     0.79%   173%

Distributions on
 preferred
 securities of
 subsidiary
 trust, net of
 income tax
 benefit of $2,388      3,630     0.04%           --     0.00%    --
                   ----------             ----------

Net income         $   67,883     0.70%   $   26,191     0.79%   159%
                   ==========             ==========

Earnings per
 share:
 Basic             $     0.65             $     0.50
 Diluted           $     0.63             $     0.49

Weighted average
 common shares
 outstanding:
 Basic                103,736                 52,354
 Diluted              111,182                 54,578


Pro forma results excluding merger costs included in the three months 
ended December 31, 2001:

Operating income   $  158,794             $   53,894
Net income         $   72,402             $   26,191

Earnings per
 share:
 Basic             $     0.70             $     0.50
 Diluted           $     0.67             $     0.49




                     AMERISOURCEBERGEN CORPORATION
                 CONDENSED CONSOLIDATED BALANCE SHEETS
                        (dollars in thousands)


ASSETS                  (Unaudited)
                         Dec. 31,      Sept. 30,        $
                           2001          2001         Change
                       ------------  ------------   -----------
Current assets:
 Cash and cash
  equivalents           $   256,689   $   297,626  ($    40,937)
 Accounts receivable,
  net                     2,106,068     2,142,663       (36,595)
 Merchandise
  inventories             5,778,905     5,056,257       722,648
 Prepaid expenses
  and other                  17,088        15,956         1,132
                        -----------   -----------   -----------
  Total current
   assets                 8,158,750     7,512,502       646,248

Long-term assets          2,774,570     2,778,743        (4,173)
                        -----------   -----------   -----------

  Total assets          $10,933,320   $10,291,245   $   642,075
                        ===========   ===========   ===========


LIABILITIES AND 
 STOCKHOLDERS' EQUITY

Current liabilities:
 Accounts payable       $ 5,122,086   $ 4,991,884   $   130,202
 Other current
  liabilities               585,114       540,569        44,545
                        -----------   -----------   -----------
  Total  current
   liabilities            5,707,200     5,532,453       174,747

Long-term debt,
 less current portion     1,989,357     1,597,295       392,062

Other liabilities            43,926        48,317        (4,391)

Company-obligated
 mandatorily redeemable
 preferred securities
 of subsidiary trust        274,784       274,616           168

Stockholders' equity      2,918,053     2,838,564        79,489
                        -----------   -----------   -----------

  Total liabilities and
   stockholders' equity $10,933,320   $10,291,245   $   642,075
                        ===========   ===========   ===========




                     AMERISOURCEBERGEN CORPORATION
                      SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)


                            Three Months Ended December 31,
                    --------------------------------------------------
                                               Pro              Pro
                      Actual     Actual       forma   Actual % forma %
Operating Revenue      2001       2000       2000 (1)  Change   Change
----------------------------------------------------------------------

Pharmaceutical
 Distribution      $9,522,076  $3,306,751  $7,929,966    188      20
PharMerica            355,415           -     335,166      -       6
Intersegment
 Eliminations        (191,215)          -    (181,597)     -       5
                   ----------- ----------- ----------- --------------

   Operating
    revenue        $9,686,276  $3,306,751  $8,083,535    193      20
                   =========== =========== =========== ==============




                            Three Months Ended December 31,
                    --------------------------------------------------
                                               Pro               Pro
Operating            Actual      Actual       forma   Actual % forma %
 Income (2)           2001        2000       2000 (1)  Change   Change
----------------------------------------------------------------------

Pharmaceutical
  Distribution       $139,484     $53,894    $116,090    159      20
PharMerica             19,310           -      17,107      -      13
                   ----------- ----------- ----------- --------------

  Operating
   income            $158,794     $53,894    $133,197    195      19
                   =========== =========== =========== ==============



Percentages of operating revenue (2):

Pharmaceutical
  Distribution
   Gross profit          3.70%       4.16%       4.06%
   Operating
    expenses             2.23%       2.53%       2.60%
   Operating
    income               1.46%       1.63%       1.46%

PharMerica
   Gross profit         33.62%           -      35.85%
   Operating
    expenses            28.18%           -      30.74%
   Operating
    income               5.43%           -       5.10%

AmerisourceBergen
 Corporation
   Gross profit          4.87%       4.16%       5.47%
   Operating
    expenses             3.23%       2.53%       3.82%
   Operating
    income               1.64%       1.63%       1.65%


    (1) Represents the combination of AmeriSource Health Corporation's
        and Bergen Brunswig Corporation's previously reported
        financial information. (See discussion under Pro Forma
        Information Appendix - A(1)).

    (2) Excludes merger costs.



                     AMERISOURCEBERGEN CORPORATION
                          EARNINGS PER SHARE
                 (In thousands, except per share data)
                              (unaudited)


    Basic earnings per share is computed on the basis of the weighted
average number of shares of common stock outstanding during the
periods presented. Diluted earnings per share is computed on the basis
of the weighted average number of shares of common stock outstanding
during the period plus the dilutive effect of stock options.
Additionally, the calculations consider the convertible subordinated
notes as if converted and, therefore, the effect of interest expense
related to those notes is added back to net income in determining
income available to common stockholders.


                                 Three months ended
                                    December 31,
                                 -------------------
                                   2001       2000
                                 --------   --------

Net income                        $67,883    $26,191
Interest expense - convertible
 subordinated notes, net of
 income taxes                       2,481        559
                                 --------   --------
Income available to common
 stockholders                     $70,364    $26,750
                                 ========   ========


Weighted average common
 shares outstanding               103,736     52,354
Effect of dilutive securities:
       Options to purchase
        common stock                1,782        993
       Convertible
        subordinated notes          5,664      1,231
                                 --------   --------

Weighted average common
 shares outstanding - diluted     111,182     54,578
                                 ========   ========


Earnings per share:
       Basic                        $0.65      $0.50
       Diluted                      $0.63      $0.49




Appendix - A(1)

                         Pro Forma Information


    The historical consolidated financial summary and summary segment
information for the three months ended December 31, 2000, included in
this press release, reflect only the results of AmeriSource Health
Corporation, as predecessor to the Company. In order to enhance
comparability, the following schedules as well as the summary segment
information include fiscal 2001 financial data on a pro forma basis.
Within these schedules, pro forma refers to the combined results of
AmeriSource Health Corporation and Bergen Brunswig Corporation and are
not intended to be consolidated financial statements of
AmerisourceBergen prepared in accordance with generally accepted
accounting principles and do not represent consolidated results as if
the merger had occurred at the beginning of the periods presented. In
addition, they are not necessarily indicative of the actual results
which might have occurred had the operations and management of
AmeriSource Health Corporation and Bergen Brunswig Corporation been
combined at the beginning of fiscal 2001.
    In addition, to enhance comparability of financial information
between fiscal years, the pro forma information for fiscal 2001
excludes the amortization of goodwill and special items related to the
merger and environmental remediation and reflects the full allocation
of Bergen Brunswig Corporation's former Corporate segment to the
Pharmaceutical Distribution and PharMerica segments.



Appendix - A(2)

AmerisourceBergen
Pro forma combined condensed financial information (1)
(dollars in thousands)

                          Fiscal Year Ended September 30, 2001
                     ----------------------------------------------
                     First Quarter   Second Quarter   Third Quarter
                     ----------------------------------------------
Operating
 revenue              $ 8,083,535     $ 8,467,976      $ 8,995,115
                     ==============================================
Gross
 profit               $   442,249     $   480,035      $   475,810

Distribution,
 selling and
 admini-
 strative (2)             293,608         303,730          295,462
Depreciation               13,891          14,337           14,296
Amortization (3)            1,553           1,140            1,270
                     ----------------------------------------------
Operating
 income               $   133,197     $   160,828      $   164,782
                     ==============================================


Gross
 profit to
 operating
 revenue                     5.47%           5.67%            5.29%
Operating
 expenses
 to
 operating
 revenue                     3.82%           3.77%            3.46%
Operating
 income to
 operating
 revenue                     1.65%           1.90%            1.83%


                          Fiscal Year Ended September 30, 2001
                     ----------------------------------------------
                              Fourth Quarter   Fiscal Year
                     ----------------------------------------------

Operating
 revenue                        $ 9,052,684    $34,599,310
                     ==============================================

Gross
 profit                         $   482,647    $ 1,880,741

Distribution,
 selling and
 admini-
 strative (2)                       304,703      1,197,503
Depreciation                         14,641         57,165
Amortization (3)                      1,427          5,390
                     ----------------------------------------------

Operating
 income                         $   161,876    $   620,683
                     ==============================================

Gross
 profit to
 operating
 revenue                               5.33%          5.44%
Operating
 expenses
 to
 operating
 revenue                               3.54%          3.64%
Operating
 income to
 operating
 revenue                               1.79%          1.79%


    (1) Represents the combination of AmeriSource Health Corporation's
        and Bergen Brunswig Corporation's previously reported
        financial information. (See discussion under Pro Forma
        Information Appendix - A(1)).

    (2) Excludes special items in the third and fourth quarters
        related to the merger and enviromental remediation.

    (3) Excludes amortization of goodwill.




Appendix - A(3)

AmerisourceBergen - Pharmaceutical Distribution
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                       Fiscal Year Ended September 30, 2001
                  --------------------------------------------
                  First Quarter  Second Quarter  Third Quarter
                  --------------------------------------------
Operating
 revenue            $7,929,966     $8,335,337     $8,835,163
                  ============================================

Gross profit          $322,096       $358,294       $358,619

Distribution,
 selling and
 administrative
 (2), (3)              195,464        202,915        200,042
Depreciation             9,426          9,962          9,916
Amortization (4)         1,116            703            835
                  --------------------------------------------

Operating income      $116,090       $144,714       $147,826
                  ============================================


Gross profit to
 operating revenue       4.06%          4.30%          4.06%
Operating expenses
 to operating
 revenue                 2.60%          2.56%          2.39%
Operating income
 to operating
 revenue                 1.46%          1.74%          1.67%


----------------------------------------------------------------------
                    Fiscal Year Ended September 30, 2001
                    ------------------------------------
                       Fourth Quarter     Fiscal Year
                    ------------------------------------

Operating
 revenue                 $8,885,145     $33,985,611
                    ====================================

Gross profit               $365,948      $1,404,957

Distribution,
 selling and
 administrative
 (2), (3)                   211,501         809,922
Depreciation                 10,278          39,582
Amortization (4)                972           3,626
                    ------------------------------------

Operating income           $143,197        $551,827
                    ====================================


Gross profit to
 operating revenue            4.12%           4.13%
Operating expenses
 to operating
 revenue                      2.51%           2.51%
Operating income
 to operating
 revenue                      1.61%           1.62%


(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).

(2) Excludes special items in the fourth quarter related to the merger
    and enviromental remediation.

(3) Expenses previously reported in the Corporate segment for Bergen
    Brunswig Corporation have been fully allocated to the
    Pharmaceutical Distribution and PharMerica segments for
    comparative purposes within this schedule.

(4) Excludes amortization of goodwill.



Appendix - A(4)
AmerisourceBergen - PharMerica
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                           Fiscal Year Ended September 30, 2001
                        ----------------------------------------------
                           First         Second          Third
                          Quarter        Quarter        Quarter
----------------------------------------------------------------------

Operating
 revenue                $  335,166     $  339,924     $  336,783
                        ========================================

Gross profit            $  120,153     $  121,741     $  117,191

Distribution,
 selling and
 administrative
 (2), (3)                   98,144        100,815         95,420
Depreciation                 4,465          4,375          4,380
Amortization
 (4)                           437            437            435
                        ----------------------------------------
Operating
 income                 $   17,107     $   16,114     $   16,956
                        ========================================

Gross profit to
 operating
 revenue                     35.85%         35.81%         34.80%
Operating
 expenses to
 operating
 revenue                     30.74%         31.07%         29.76%
Operating
 income to
 operating
 revenue                      5.10%          4.74%          5.03%


----------------------------------------------------------------------
                        Fiscal Year Ended September 30, 2001
                        ------------------------------------
                             Fourth               Fiscal 
                             Quarter               Year
----------------------------------------------------------------------

Operating
 revenue                    $  338,135          $1,350,008
                            ==============================

Gross profit                $  116,699          $  475,784

Distribution,
 selling and
 administrative
 (2), (3)                       93,202             387,581
Depreciation                     4,363              17,583
Amortization
 (4)                               455               1,764
                            ------------------------------
Operating
 income                     $   18,679          $   68,856
                            ==============================

Gross profit to
 operating
 revenue                         34.51%              35.24%
Operating
 expenses to
 operating
 revenue                         28.99%              30.14%
Operating
 income to
 operating
 revenue                          5.52%               5.10%


(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).

(2) Excludes special items in the fourth quarter related to the merger
    and enviromental remediation.

(3) Expenses previously reported in the Corporate segment for Bergen
    Brunswig Corporation have been fully allocated to the
    Pharmaceutical Distribution and PharMerica segments for
    comparative purposes within this schedule.

(4) Excludes amortization of goodwill.



Appendix - A(5)
AmerisourceBergen - Intersegment Eliminations
Pro forma combined condensed financial information (1)
(dollars in thousands)
----------------------------------------------------------------------
                       Fiscal Year Ended September 30, 2001
             --------------------------------------------------------
              First      Second       Third      Fourth      Fiscal
             Quarter     Quarter     Quarter     Quarter      Year
----------------------------------------------------------------------

Operating
 revenue    ($181,597)  ($207,285)  ($176,831)  ($170,596)  ($736,309)
             ========================================================
Gross
 profit      $      0    $      0    $      0    $      0    $      0

Distri-
 bution,
 selling and
 admini-
 strative           -           -           -           -           -
Depreciation        -           -           -           -           -
Amortization        -           -           -           -           -
             --------------------------------------------------------

Operating
 income      $      0    $      0    $      0    $      0    $      0
             ========================================================

(1) Represents the combination of AmeriSource Health Corporation's and
    Bergen Brunswig Corporation's previously reported financial
    information. (See discussion under Pro Forma Information Appendix
    - A(1)).

CONTACT: AmerisourceBergen
Michael N. Kilpatric, 610/727-7118
mkilpatric@amerisource.com


Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..

Learn More